InvestSMART

Immuron Limited (ASX: IMC) - Announcements

- Current share price for IMC : $0.046

ASX company news and announcements for Immuron Limited (IMC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immuron Limited (IMC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immuron Limited (IMC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immuron Limited (IMC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$15 Immurons NASH Phase II Trial Achieves 100 Patient Milestone 28 Oct 2016 11:09AM $0.355 $0.046 fallen by 87.04%
$15 Appendix 3Y - Change in Director's Interest Notice (DP) 27 Oct 2016 4:26PM $0.355 $0.046 fallen by 87.04%
$15 Becoming a substantial holder 17 Oct 2016 6:40PM $0.365 $0.046 fallen by 87.40%
$15 NASH Phase II Trial reaches 75% of Patient Recruitment 10 Oct 2016 10:37AM $0.250 $0.046 fallen by 81.60%
$15 NASH Assets In Demand - Allergan Acquires Tobira for US$1.7B 5 Oct 2016 12:01AM $0.245 $0.046 fallen by 81.22%
$15 IMC - ASX - Appendix 3B (Rights Issue) 4 Oct 2016 10:55AM $0.245 $0.046 fallen by 81.22%
$15 Immurons $6M Rights Issue Closes Oversubscribed 4 Oct 2016 10:48AM $0.245 $0.046 fallen by 81.22%
$15 Appendix 4G 30 Aug 2016 2:27PM $0.295 $0.046 fallen by 84.41%
$15 Appendix 4E and Annual Report 30 Aug 2016 2:27PM $0.295 $0.046 fallen by 84.41%
$15 Immuron Expands Collaborate with US Navy 30 Aug 2016 10:40AM $0.300 $0.046 fallen by 84.67%
$15 US NIH to Fund Second IMC Fatty Liver Study - Pediatric NASH 18 Aug 2016 11:28AM $0.300 $0.046 fallen by 84.67%
$15 Travelan to be Stocked by US Distributor Medique Products 8 Aug 2016 9:54AM $0.285 $0.046 fallen by 83.86%
$15 Immuron to Seek Approval of Rights Issue Options at AGM 2 Aug 2016 5:07PM $0.250 $0.046 fallen by 81.60%
$15 Immuron to Cooperate with Universities on Autism Research 20 Jul 2016 8:43AM $0.245 $0.046 fallen by 81.22%
$15 Immuron to repay outstanding Convertible Note in cash 18 Jul 2016 8:44AM $0.230 $0.046 fallen by 80%
$15 Form 604 -Change in Substantial Shareholding (Inverarey P/L) 15 Jul 2016 2:48PM $0.230 $0.046 fallen by 80%
$15 Appendix 3Y - Change in Director's Interest Notices (x4) 11 Jul 2016 10:40AM $0.235 $0.046 fallen by 80.43%
$15 Appendix 3B for Rights Issue & New Top 20 Shareholder List 7 Jul 2016 11:59AM $0.250 $0.046 fallen by 81.60%
$15 Immuron Rights Issue Raises $5.33M 5 Jul 2016 3:40PM $0.250 $0.046 fallen by 81.60%
$15 IMC Signs Shigella Vaccine Developmt Agreement with US Army 21 Jun 2016 9:36AM $0.260 $0.046 fallen by 82.31%
$15 Immuron Newsletter - June 2016 20 Jun 2016 12:05PM $0.255 $0.046 fallen by 81.96%
$15 Travelan and Protectyn Are Now Available For Sale in China 16 Jun 2016 9:40AM $0.245 $0.046 fallen by 81.22%
$15 Immuron Extends Closing Date of $6M Rights Issue 14 Jun 2016 4:30PM $0.245 $0.046 fallen by 81.22%
$15 Travelan to Reach Upto 1.5M New US Customers via Magellans 14 Jun 2016 10:11AM $0.245 $0.046 fallen by 81.22%
$15 Immuron Company Presentation - May 2016 31 May 2016 10:12AM $0.330 $0.046 fallen by 86.06%

601 - 625 of 782 results

Page 25 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.